Researchers sought to determine whether subcutaneous isatuximab would be an effective treatment for patients with RRMM.

Imugene Ltd (ASX:IMU) CEO Leslie Chong sits down with Jonathan Jackson in the Proactive studio to delve into the company’s latest milestone - commencement of dosing for the first patient in the ...

KaliVir Immunotherapeutics, Inc., a clinical-stage biotechnology company developing cutting-edge, multi-mechanistic oncolytic immunotherapy programs, today announced the successful completion of the ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window CHICAGO -- ...

CHICAGO — Administering the bispecific antibody amivantamab (Rybrevant) subcutaneously rather than intravenously in combination with lazertinib (Leclaza) not only reduces administration times but also ...